Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
|
|
- Cordelia Bennett
- 5 years ago
- Views:
Transcription
1 Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global Diabetes Program, Parkland Health & Hospital System
2 Agenda Brief history of insulin development ADA guidelines for insulin management Longer-acting basal insulin analogs Faster-acting insulin aspart Fixed-ratio combinations with insulin + GLP-1 agonists Resurgence of Regular U500
3 FDA approved medications to treat diabetes 74 Gourgari et al. Journal of Diabetes and Its Complications 31 (2017)
4 Historical approval of insulin preparations by the FDA Humulin R U500 Humulin R U100 Humulin NPH Humulin 70/30 Novolin 70/30 Novolin R U100 Novolin NPH Humalog U100 Humalog 50/50 Humalog 75/25 Lantus Novolog 70/30 Apidra Levemir Afrezza Toujeo U300 Humalog U200 Tresiba Ryzodeg 70/30 Basaglar Soliqua Xultophy FIASP Admelog
5 Insulin products marketed in the US Prandial Basal Combinations Short-acting Regular U100 (Humulin R, Novolin R, ReliOn R) Regular U500 (Humulin U500) Rapid-acting Glulisine (Apidra) Aspart (Novolog) Lispro (Humalog U100 & U200, Admelog) Faster-acting aspart (FIASP) Inhaled Technosphere insulin (Afrezza) Post-prandial control Intermediate, basal NPH (Humulin N, Novolin N, Relion N) Basal analogs Glargine U100 (Lantus, Basaglar) Detemir (Levemir) Longer-acting basal analogs Degludec (Tresiba U100 & U200) Glargine U300 (Toujeo) Fasting control Adapted from Meneghini LF. New insulin preparations: a primer for the clinician. Cleveland Clinic Journal of Medicine 2016; 83(1): S43-S49 Pre-mixed Insulin 70/30 (Regular, Novolog Mix) Insulin 75/25 (Humalog Mix) Degludec/aspart 70/30 (Ryzodeg) Aspart 50/50 (Humalog Mix) Fixed-ration combinations Glargine U100/Lixisenatide (Soliqua) Degludec U100/Liraglutide (Xultophy) Fasting & post-prandial control
6 Insulin products marketed in the US Prandial Basal Combinations Short-acting Regular U100 (Humulin R, Novolin R, ReliOn R) Regular U500 (Humulin U500) Rapid-acting Glulisine (Apidra) Aspart (Novolog) Lispro (Humalog U100 & U200, Admelog) Faster-acting aspart (FIASP) Inhaled Technosphere insulin (Afrezza) Post-prandial control Intermediate, basal NPH (Humulin N, Novolin N, Relion N) Basal analogs Glargine U100 (Lantus, Basaglar) Detemir (Levemir) Longer-acting basal analogs Degludec (Tresiba U100 & U200) Glargine U300 (Toujeo) Fasting control Adapted from Meneghini LF. New insulin preparations: a primer for the clinician. Cleveland Clinic Journal of Medicine 2016; 83(1): S43-S49 Pre-mixed Insulin 70/30 (Regular, Novolog Mix) Insulin 75/25 (Humalog Mix) Degludec/aspart 70/30 (Ryzodeg) Aspart 50/50 (Humalog Mix) Fixed-ration combinations Glargine U100/Lixisenatide (Soliqua) Degludec U100/Liraglutide (Xultophy) Fasting & post-prandial control
7 ADA Guidelines on injectable therapy Diabetes Care 2018; 41 (Suppl. 1): S73-S85
8 Basal insulin replacement
9 Basal Insulin Analogs towards flatter, longer, and more consistent biologic profiles Mathieu, et al. Nature Reviews 2017; 13:
10 Biologic activity & mode of protraction Mathieu, et al. Nature Reviews 2017; 13:
11 Basal Insulin Efficacy in lowering A1C NPH = Glargine U100 = Detemir* = Degludec = Glargine U300* = Glargine U100 biosimilars * May require 10%-15% more units.
12 GIR, mg/kg/min Action of Long vs Ultralong-Acting Insulins 3 2 U-100 glargine (0.4 U/kg) 1,a U-300 glargine (0.4 U/kg) 1,2,b U-100 degludec (0.4 U/kg) 2,b,c Time After Injection, hours 1. Becker RH, et al. Diabetes Care. 2015;38: ; 2. US FDA. Drugs@FDA Heise T, et al. Diabetes. 2012;61(suppl 1):A91 [abstract 349-OR].
13 Longer-acting basal analogs have lower hypoglycemia risk (esp. nocturnal) than glargine U100 Hypoglycemia Risk Glargine U300 Degludec < Glargine U100 < NPH Becker RH, et al. Diabetes Care. 2015;38: US FDA. Heise T, et al. Diabetes. 2012;61(Suppl 1):A91 [abstract 349-OR]. Bolli GB, et al. Diabetes Obes Metab. 2015;17:
14 3-Point MACE 0.91 HbA 1c Reduction = Severe Hypoglycemia Overall Nocturnal -40% -53% Values in red are statistically significant. MACE, major adverse cardiovascular event. Marso SP, et al. NEJM 2017; 377:
15 Basal Insulin Replacement Options: Hypo Risk vs Cost Cost ($) Degludec $312 Glargine U300 $203 Detemir $284 Glargine U100 $178 NPH $28 Hypoglycemia risk Cost of 1000 units of insulin from GoodR x based on Walmart pricing (pens or vials, when available). Accessed October 3, 2017.
16 When Might Ultra Long-Acting Insulin Be Considered? Patients experiencing nocturnal hypoglycemia with current basal insulins (glargine U100) Patient on small basal insulins doses not lasting throughout the day (i.e. <20 u/day) Specific insulin requiring populations Cystic fibrosis Hypoglycemia unawareness Very thin
17 What time of the day do you start the basal insulin? > = NPH Detemir Glargine U100 Glargine U300 Degludec
18 Average glucose profiles, mean (SE), mg/dl 24-hour glucose profile of AM vs PM administration of Gla-100 or Gla-300 in T1DM 201 Gla Gla Morning Evening Time, h Morning Evening Time, h Average 24-h glucose profiles during the last 2 weeks of each treatment period Bergenstal RM, et al. Diabetes Care 2017;40:554 60
19 Basal insulin Up-titration: Practical Tips Glycemic targets FPG < 130 mg/dl & A1C < 7% FPG < 150 mg/dl & A1C < 8% MD or patient driven Titration algorithms or 1unit:1day 3units:3days 2,4,6,8units:7days or
20 Basal insulin titration above 0.5 units/kg/day associated with more weight gain and hypoglycemia risk & less impact on A1C Reid T, et al. Int J Clin Pract. 2016;70(1): N=2837 insulin-naïve T2D Patients requiring 0.5 u/kg/d had higher baseline A1C, were younger, & had shorter diabetes duration
21 Total Hyperglycemia (%) Glycemic contributions after optimizing basal insulin therapy Basal hyperglycemia Postprandial hyperglycemia <6.5% 6.5-<7.0% 7.0-<7.5% 7.5-<8.0% 8.0% Baseline HbA1c Category (%) Riddle MC, et al. Diabetes Care. 2011:34:
22 Going beyond basal insulin therapy Post-prandial glycemic control
23 Adding Prandial Insulin to Basal Therapy Further Improves HbA 1C Davies M et al Diabetes Obes Metab May;10(5):
24 Adding sequential prandial boluses to basal insulin therapy Identify the largest meal of the day Start 4-6 units of prandial insulin Adjust dose based on SMBG Most patients need around units before meals If A1C still above target after optimization of 1 st bolus, add 2 nd prandial bolus Hypoglycemia risk increases with each additional bolus Meneghini LF, et al. Endocr Pract. 2011; 17:
25 Biologic activity & mode of protraction Mathieu, et al. Nature Reviews 2017; 13:
26 Faster-Acting Insulin Aspart (FIASP) versus Regular insulin and other prandial analogs Price/vial $24 $289 $ Faster-acting insulin aspart Consider when: Need better postprandial control Post-meal dosing Insulin pumps Pregnancy? Mathieu, et al. Nature Reviews 2017; 13:
27 Faster-Acting Insulin Aspart (FIASP) versus Regular insulin and other prandial analogs Price/5 pens n/a $550 $ Faster-acting insulin aspart Consider when: Need better postprandial control Post-meal dosing Insulin pumps Pregnancy? Mathieu, et al. Nature Reviews 2017; 13:
28 Adding GLP-1 agonists to basal insulin
29 Basal Insulin Intensification: GLP-1 RA vs Prandial Insulin Meta-Analysis A1C 7.0% a Equivalent glycemic control (P = NS) 2,3 I 2 = 12.0% Favors basal-bolus insulin Favors GLP-1 + basal insulin Relative Risk (95% CI) 1.01 (0.85, 1.21) 1.20 (0.92, 1.57) 1.07 (0.91, 1.26) Weight 67.70% 32.30% % Hypoglycemia, EPY b 33% lower risk with GLP-1 RA (P <.05) 2-4 Relative Risk (95% CI) Weight 0.70 (0.55, 0.90) 0.14 (0.01, 2.65) 0.37% 0.65 (0.50, 0.83) 50.42% 49.21% 0.67 (0.56, 0.80) % I 2 = 0.0% Favors GLP-1 + basal-bolus insulin Δ Weight, kg a 5.66 kg more weight loss with GLP-1 RA (P <.05) 2-4 I 2 = 98.7% Favors basal-bolus insulin Weighted Mean Difference (95% CI) (-5.33, -3.87) (2.06, -0.94) (-12.59, -9.55) (-9.80, -1.51) Weight 33.66% 33.81% 32.53% % Favors GLP-1 + basal-bolus insulin Favors basal-bolus insulin a Baseline to the end of the intervention; b Any hypoglycemic episode, as defined by the trial. Eng C, et al. Lancet. 2014;384: Diamant M, et al. Diabetes Care. 2014; 37: Rosenstock J. et al. Diabetes Care. 2014:37: Shao H, et al. Diabetes Metab Res Rev. 2014:30:
30 What can we expect when combining a GLP-1 RA and a basal insulin in one pen? Efficacy Side effects HbA 1c FPG PPG WEIGHT HYPOGLYCAEMIA NAUSEA GLP-1 RA monotherapy Basal insulin GLP-1 RA/insulin combined FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide-1 receptor agonist; PPG, postprandial glucose
31 Fixed-Ratio Combination of basal insulin + GLP-1 agonists in clinical practice Indicated in T2DM not controlled on basal insulin or GLP-1 agonist therapy alone mg lira/1 unit degludec 0.33 ug lixi/1 unit glargine U100 Weekly titration Max dose Degludec 50 units Liraglutide 1.8 mg Max dose Glargine 60 units Lixisenatide 20 μg
32 Mean HbA 1c (%) Real-world observational study of patients switching to degludec/liraglutide fixed ratio combination 9.5 Change in HbA 1c over 6 months % % 8.6% 8.3% 8.3% 8.3% %* -1.6%* -1.0%* -0.9%* -0.7%* -0.6%* % 7.3% 7.5% 7.4% 7.6% 7.6% Overall (n=566) Non-injectable therapy (n=112) GLP-1RA ±OAD (n=57) Basal ±OAD (n=109) Insulin MDI ±OAD (n=153) Insulin & GLP-1RA ±OAD (n=135) *p< Data based on effectiveness analysis set n, number of patients with data at both time points; GLP-1 RA, glucagon like peptide-1 receptor agonist; OAD, oral antidiabetic drugs; MDI, multiple dose insulin injection Price et al. ADA 2017;988-P.
33 Concentrated Regular Insulin U500
34 Indication Improve glycemic control in adults and children with diabetes mellitus requiring > 200 units of insulin per day
35 Regular insulin U500 meta-analysis % 9.6% 9.8% 10.0% 9.9% 9.4% 10.1% 9.1% 9.5% Baseline A1C Mean TDD at baseline units Meant change in TDD 52 units Mean weight change 4.4 kg Garg Neal Wafa Nayyar Davidson Dailey Boldo Ziesmer Quinn Overall Reutrakul S, et al. J Diab Science Tech 2012; 6(2):
36 Mean Serum IRI Concentration (pmol/l) Glucose Infusion Rate (mg/min) PK/PD Profiles for Regular U-500 vs U-100 Human Insulin Regular U-100 Regular U-500 5x more concentrated ⅕ the volume Unit Dose Unit Dose Time (hours) Time (hours) de la Peña A, et al. Diabetes Care. 2011;34:
37 Regular U-500 Insulin Use pen or U500 syringe to administer Can inject BID or TID BID = 60% / 40% TID = 40% / 30% / 30% = 100 U of U-100 insulin in a U-100 insulin syringe (100 unit markings) 100 U of U-500 insulin in a U-500 insulin syringe (20 unit markings) This shows the same dose (actual U) (1) Humulin R U500 PI (2) Eli Lilly and Company. Humulin R U-500 KwikPen Available from:
38 Example of conversion to Regular U y/o on aspart insulin 40 U with meals and glargine U100 insulin 80 U BID TDD = 280 U per day or 2.3 U/kg/day 120 kg Regular U500 BID (60/40): 168 U in AM and 112 U before dinner Regular U500 TID (40/30/30): 112 U in AM, 84 U at lunch & dinner
39 Summary Longer-acting basal insulin formulations have similar A1C lowering effect, but lower risk of overnight hypoglycemia More flexible dosing during the day For patients whose A1C remains elevated on > 0.5 U/kg/day, consider adding prandial coverage Faster-acting insulin preparations improve post-prandial hyperglycemia in select individuals Fixed-ratio combinations offer improved glycemic control with weight benefit and low hypoglycemia risk In individuals on > 200 U of insulin a day, consider U500 (probably to improve adherence)
40
Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationWhat's New in Insulin Related Therapies 2018
What's New in Insulin Related Therapies 2018 James Lenhard, MD (JLenhard@ChristianaCare.org) Section Chief, Endocrinology and Metabolism Christiana Care Health System Newark, DE Disclosures Speaker:Eli
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationConverting lantus to humalog 75 25
P ford residence southampton, ny Converting lantus to humalog 75 25 This page includes the following topics and synonyms: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes. Thiazide
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationCOPYRIGHT. Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine December 5, Richard S.
Advancing to Insulin Replacement Therapy: When, Why, and How? Update in Internal Medicine - 2016 December 5, 2016 Richard S. Beaser, MD Medical Director, Professional Education Joslin Diabetes Center Associate
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationInsulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM
Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM University of Mississippi School of Pharmacy Joshua J. Neumiller, Pharm.D., CDE, FAADE,
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More information8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations
UNRAVELING THE CROWED INSULIN SCENE A Practical Overview of Insulin Focusing on New Insulin Preparations Patricia Garnica MS, ANP-BC, CDE, CDTC North Shore University Hospital, Manhasset, N.Y. October
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More information6/5/18. Emerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long- Acting Insulins
Emerging Challenges in Primary Care: 218 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long- Acting Insulins Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationEmerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins
Emerging Challenges in Primary Care: 2018 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationIndividualizing Therapy int2dm With Insulin
Individualizing Therapy int2dm With Insulin Etie Moghissi, MD, FACP, FACE Clinical Associate Professor University of California, Los Angeles Los Angeles, California OBJECTIVES: At the conclusion of this
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationBasal Insulin T1 & T2
Initiation, Titration And Maintenance Of Basal Insulin In Type 1 Versus Type 2 Diabetes: An Important Foundation To uccessful Insulin Management teven Edelman, MD Clinical Professor Of Medicine University
More informationThe fi rst isolation and successful extraction of
LUIGI MENEGHINI, MD, MBA Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, TX New insulin preparations:
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationSession 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives
Session 3: Insulin Strategies for Primary Care Providers: Addressing a Core Defect in Diabetes Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin, and
More informationNatural History of Type 2 Diabetes
Key Points About Insulin to Discuss Today We should be using insulin earlier in the natural history of type 2 diabetes How early and how do we know when to start insulin? Barriers to insulin therapy Goals
More informationDrug List. Drug List (cont d) Objectives. Case and Initial CME Questions. Presenter Disclosure Information
:3 :5 PM How to Select and Initiate Insulin Therapy in the Type Diabetes Patient SPEAKERS Intekhab Ahmed, MD, FACE, FACP Felice Caldarella, MD, FACE, FACP, CDE Presenter Disclosure Information The following
More informationInsulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018
Insulins: Prices, Rebates, and Other Factors Influencing Costs May 2018 Introduction: Types of Insulin Types of Insulin Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from
More information9/8/2016. Faculty. Examining the Role of Long-Acting Insulin within the Physiologic Approach to Glucose Control. Disclosures. Learning Objectives
9/8/21 Faculty Examining the Role of Long-Acting within the Physiologic Approach to Glucose Control Dace Trence, MD, FACE Professor, Division of Metabolism, Endocrinology and Nutrition Director, Diabetes
More informationOHSU Drug Effectiveness Review Project Summary Report Long-Acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationT2DM and Need for Insulin. Insulin Pharmacokinetics. When To Start Insulin in T2DM. FDA-approved Insulins for Subcutaneous Injection
Plasma Insulin Levels Patients Requiring Insulin (%) Effective Use of Insulin in the Primary Care Practice: Insulin Therapy Initiation, Intensification, and the Insulinizing Complex Patients with T2DM:
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationInsulin Management and Advancing Practice of the Registered Dietitian Nutritionist (RDN) in Diabetes Care
Insulin Management and Advancing Practice of the Registered Dietitian Nutritionist (RDN) in Diabetes Care Patricia Davidson, DCN, RDN, CDE, LDN, FAND West Chester University of Pennsylvania West Chester,
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More information5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:
Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,
More informationDiabetes and Chronic Kidney Disease DR. JEREMY GILBERT, MD FRCPC ASSISTANT PROFESSOR, U OF T
Diabetes and Chronic Kidney Disease DR. JEREMY GILBERT, MD FRCPC ASSISTANT PROFESSOR, U OF T Objectives Recognize the impact that CKD has on diabetes management Review the current Canadian Diabetes Association
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationConversion of lantus to toujeo
Conversion of lantus to toujeo Search The dosing information for Toujeo recommends decreasing the total insulin dose to 80% of the daily requirement of Toujeo when switching from to. Watch a video to learn
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
Learning Objectives Understand and appropriately individualize treatments based on evidencebased guideline recommendations across the continuum of care in patients with T2DM Key = Clinical Pearl Identify
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationIndividualizing Therapy in T2DM With Insulin
Developed by the Institute for Individualizing Therapy in TDM With Insulin Davida F Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Division of Endocrinology, Diabetes, and Bone and Mineral Disorders
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationInsulin Drug Class Update
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE
ORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE key objectivies UNDERSTAND HOW TO DEFINE ORAL and INGECTABLE AGENT FAILURES understand benefit of QUADRUPLE oral agents vs
More informationWhat to Do After Basal Insulin
BasalINSULIN What to Do After Basal Insulin 3 Treatment Strategies for Type 2 Diabetes These strategies can help you optimize glucose control in your patient with type 2 diabetes when basal insulin alone
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationDegludec lantus conversion
Degludec lantus conversion Search embarazadas con elevado riesgo de enfermedad tiroidea usando la. There are various possible causes of a high blood sugar level in the morning: The Dawn Phenomenon which
More informationInsulin Therapies for T2DM
Insulin Therapies for T2DM Defects in T2DM Decreased insulin secretion Inefficient glucose uptake (skeletal muscles) Increased hepatic glucose production Decreased incretin effect Increased glucagon secretion
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More information